Cargando…

Outcome of MS relapses in the era of disease-modifying therapy

BACKGROUND: In multiple sclerosis (MS), neurological disability results from incomplete remission of relapses and from relapse-independent progression. Intravenous high dose methylprednisolone (IVMP) is the established standard treatment to accelerate clinical relapse remission, although some patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stoppe, Muriel, Busch, Maria, Krizek, Luise, Then Bergh, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547454/ https://www.ncbi.nlm.nih.gov/pubmed/28784102 http://dx.doi.org/10.1186/s12883-017-0927-x

Ejemplares similares

Switching to second line MS disease-modifying therapies is associated with decreased relapse rate
por: Marriott, James John, et al.
Publicado: (2023)

Motor Sequence Learning across Multiple Sessions Is Not Facilitated by Targeting Consolidation with Posttraining tDCS in Patients with Progressive Multiple Sclerosis
por: Seelmann-Eggebert, Harald, et al.
Publicado: (2021)

Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS
por: Houtchens, Maria K., et al.
Publicado: (2018)

Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?
por: Maguire, Cole, et al.
Publicado: (2020)

COVID-19 and MS disease-modifying therapies
por: Berger, Joseph R., et al.
Publicado: (2020)

Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
por: Chylińska, Magdalena, et al.
Publicado: (2023)

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
por: Strijbis, EMM, et al.
Publicado: (2023)

B-cell–targeted therapies in relapsing forms of MS
por: Dubey, Divyanshu, et al.
Publicado: (2017)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Disease-modifying therapies alter gut microbial composition in MS
por: Katz Sand, Ilana, et al.
Publicado: (2018)

The COVID-19 pandemic and the use of MS disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2020)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
por: Nash, Richard A., et al.
Publicado: (2017)

Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
por: Holroyd, Kathryn B., et al.
Publicado: (2022)

Effect of vitamin D on MS activity by disease-modifying therapy class
por: Rotstein, Dalia L., et al.
Publicado: (2015)

Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies
por: McFaul, Derek, et al.
Publicado: (2021)

Effects of MS disease-modifying therapies on responses to vaccinations: A review.
por: Ciotti, John Robert, et al.
Publicado: (2020)

Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
por: Smith, Tyler E, et al.
Publicado: (2022)

Modified ERAS protocol using preoperative oral rehydration therapy: outcomes and issues
por: Taniguchi, Hideki, et al.
Publicado: (2014)

Detecting isolated cognitive relapses in persons with MS
por: Morrow, Sarah A, et al.
Publicado: (2023)

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS
por: Ribbons, Karen Ann, et al.
Publicado: (2015)

Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)

The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
por: Pardo, Gabriel, et al.
Publicado: (2017)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
por: Kantor, Daniel, et al.
Publicado: (2023)

Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Abdel-mannan, Omar A., et al.
Publicado: (2021)

Drugs, bugs, and MS: The interplay between disease-modifying therapy and gut microbiota
por: Mangalam, Ashutosh K.
Publicado: (2018)

Relapse and Outcome of Lupus Nephritis After Renal Transplantation in the Modern Immunosuppressive Era
por: Pattanaik, Debendra, et al.
Publicado: (2022)

The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study
por: Lenz, Florian, et al.
Publicado: (2020)

Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2018)

Relapsing and progressive MS: the sex-specific perspective
por: Rommer, Paulus Stefan, et al.
Publicado: (2020)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
por: Kim, Su-Hyun, et al.
Publicado: (2019)

Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey
por: Coratti, Giorgia, et al.
Publicado: (2023)

Relapsing–Remitting Multiple Sclerosis: Patterns of Response to Disease-Modifying Therapies and Associated Factors: A National Survey
por: Sá, Maria José, et al.
Publicado: (2014)

Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
por: Fernández, Oscar, et al.
Publicado: (2017)

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
por: Lapuz, Carminia, et al.
Publicado: (2018)

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
por: Sormani, Maria Pia, et al.
Publicado: (2021)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study
por: Kallmann, Boris A., et al.
Publicado: (2019)

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
por: D’Amico, Emanuele, et al.
Publicado: (2021)

How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?
por: Giovannoni, Gavin
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j1om1a9t9cchg1i9ehjrf30rbm